RecruitingPhase 2NCT05116930

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study


Sponsor

Mayo Clinic

Enrollment

18 participants

Start Date

Nov 19, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 54 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Glycopyrrolate and a drug called Neostigmine for people with post dural puncture headache.. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 54 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeostigmine

IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

DRUGGlycopyrrolate

IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses


Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05116930


Related Trials